2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh

Plenary Session

Vinay Prasad, MD MPH

Medicine, Policy, Health, Science & Medicine, Oncology

4.8 • 799 Ratings

🗓️ 8 October 2019

⏱️ 82 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

We start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has Become Available?". BEACON: doi.org/10.1056/NEJMoa1908075 Subacute Rehabilitation: doi.org/10.1200/JOP.19.00044 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Plenary Session.
0:07.0	I'm your host, Dr. Vinay Prasad.
0:10.0	I'm a practicing hematologist, oncologist, and I'm associate professor of medicine.
0:14.0	I'm interested in issues at the intersection of medicine, oncology, and health policy, and that's what you're going to get on this podcast.
0:22.2	Welcome to Season 2.
0:26.8	This week on Plenary Session, we have a few things in store for you.
0:30.2	We're back with Question of the Week.
0:31.9	You must have missed it.
0:33.4	And we have an interview with Dr. Jonathan Yeh from Johns Hopkins Medical School,
0:37.9	and he's going to talk about what happens when patients get discharged from the hospital from the oncology
0:42.7	ward with a plan to go to subacute rehab and get fit for subsequent therapy.
0:48.4	He'll be talking about that paper that appeared in the Journal of Oncology Practice later
0:51.9	on this episode. And of course, the long-anticipated discussion of the Beacon Study, Encaraphanib, binometineb, and cetuximab for BRAF V-600-E mutated colorectal cancer.
1:03.0	It is a chemotherapy-free regimen that's used in colorectal cancer, and it came out at ESMO 2019.
1:12.5	And it is the talk of the town.
1:14.7	And it's going to be the talk of this week's plenary session because I have turned to Twitter to criticize this study
1:18.1	as the single worst reported randomized controlled trial I have ever read.
1:24.1	And I'm going to tell you why it lives up to that billing.
1:27.4	So stay tuned. You
1:28.5	won't want to miss this. But first, a thanks. I want to thank those of you who've gone
1:39.8	online and support this podcast on patreon.com. Patreon subscribers get access to the slides from lectures I give on Plenary Session.
1:47.7	I also want to thank the hundreds of you who've gone to the iTunes store and reviewed this podcast.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.